30 Day Mortality Post Cardiac Event (Risk Scoring Systems)

Similar documents
RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Efficient Evaluation of Chest Pain

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

EMR Tutorial Acute Coronary Syndrome

HOW TO CITE THIS ARTICLE:

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Implementing a Prehospital 12-Lead Program

Main Effect of Screening for Coronary Artery Disease Using CT

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

URN: Family name: Given name(s): Address:

Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial

Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

Advancing ACS Diagnosis Using Serial Troponin Testing

Acute Coronary Syndrome

Translating Science to Health Care: the Use of Predictive Models in Decision Making

Issues and Challenges in ACS Management. Dr.Nakul Sinha MD.DM, FACC. Sahara Hospital, LUCKNOW

Redefining the NSTEACS pathway in London

Predictive value of a 6-hour ECG/troponin protocol in patients with chest pain

Tips and Tricks to Demystify 12 Lead ECG Interpretation

Ruchika D. Husa, MD, MS Assistant t Professor of Medicine in the Division of Cardiology The Ohio State University Wexner Medical Center

Management of Acute Coronary Syndrome / NSTEMI

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

Electrocardiographic Body Surface Mapping

CASE B1. Newly Diagnosed T2DM in Patient with Prior MI

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Risk stratification for patients who present to the

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

Marco Ferlini Struttura Semplice di Emodinamica, UO Cardiologia Dipartimento Cardiotoracovascolare Fondazione IRCCS, Policlinico San Matteo

Cardiac Rehabilitation An Underutilized Class I Treatment for Cardiovascular Disease

A Comprehensive Strategy for Coordinating the Care for Patients with Coronary Artery Disease (CAD) and Other Chronic Medical Conditions

How to manage a patient who needs thrombolysis in acute stroke, ablation or angioplasty/stenting? Janet M McComb Freeman Hospital Newcastle upon Tyne

Addendum to Clinical Review for NDA

Improving PCI Benchmark times in a Non-PCI World

How to Maximize Your Lab s Value to Cardiac Care Sammie Sue Hendrix Laboratory Director Citizens Medical Center, Victoria Texas

FFR CT : Clinical studies

Cilostazol versus Clopidogrel after Coronary Stenting

Priority setting for research in healthcare: an application of value of. information analysis to glycoprotein IIb/IIIa antagonists in non-st elevation

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

For the NXT Investigators

Evaluation of First-Draw Whole Blood, Point-of-Care Cardiac Markers in the Context of the Universal Definition of Myocardial Infarction

Presenter: Marco Valgimigli, MD PhD, FESC Erasmus MC, Thoraxcenter Rotterdam The Netherlands

DUAL ANTIPLATELET THERAPY. Dr Robert S Mvungi, MD(Dar), Mmed (Wits) FCP(SA), Cert.Cardio(SA) Phy Tanzania Cardiac Society Dar es Salaam Tanzania

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Antiplatelet and Antithrombotics From clinical trials to guidelines

Listen to your heart: Good Cardiovascular Health for Life

Utilization Review Cardiac Rehabilitation Services: Underutilized

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Success factors in Behavioral Medicine

Duration of Dual Antiplatelet Therapy After Coronary Stenting

Stent for Life Initiative How can we improve system delay and patients delay in STEMI

Platelet Function Testing vs Genotyping : Focus on Pharmacogenomics of Clopidogrel. Kiyuk Chang, M.D., Ph.D.

Investor science conference call: American College of Cardiology 2015

MANAGEMENT AKUTES KORONARSYNDROM: RISIKOSTRATIFIZIERUNG UND THERAPIE. Peter Wenaweser Universitätsklinik für Kardiologie

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Post-MI Cardiac Rehabilitation. Mark Mason Consultant Cardiologist Harefield Hospital Royal Brompton and Harefield NHS Foundation Trust

A list of FDA-approved testosterone products can be found by searching for testosterone at

Non-invasive functional testing in 2014

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

ST Segment Elevation Nothing is ever as hard (or easy) as it looks

CARDIAC RISKS OF NON CARDIAC SURGERY

Section 8: Clinical Exercise Testing. a maximal GXT?

CAREER PATHS IN QUALITY

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Monitoring acute coronary syndrome using national hospital data An information paper on trends and issues

Chest Pain in the Emergency Room. A Multicenter Validation of the HEART Score

Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators

The largest clinical study of Bayer's Xarelto (rivaroxaban) Wednesday, 14 November :38

ACTION Registry - GWTG: Defect Free Care for Acute Myocardial Infarction Specifications and Testing Overview

Quality Improvement. Quantified. TM. Program Overview July, 2008

Anticoagulation For Atrial Fibrillation

WOEST TRIAL- NO ASPIRIN IN STENTED PATIENTS REQUIRING ANTICOAGULATION. Van Crisco, MD, FACC, FSCAI First Coast

Barriers to Healthcare Services for People with Mental Disorders. Cardiovascular disorders and diabetes in people with severe mental illness

Marquette 12SL Algorithm. Connected Clinical Excellence

Epinephrine in CPR. The 5 Most Important EMS Articles EAGLES Epi vs No-Epi Take Homes 2/28/2014. VF/VT (1990 Pairs) Epi vs No-Epi

The 5 Most Important EMS Articles EAGLES 2014

Perioperative Cardiac Evaluation

Chest Pain. Acute Myocardial Infarction: Differential Diagnosis and Patient Management. Common complaint in ED. Wide range of etiologies

Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

Remote Delivery of Cardiac Rehabilitation

Variation of Cardiac Troponin I and T Measured with Sensitive Assays in Emergency Department Patients with Noncardiac Chest Pain

James F. Kravec, M.D., F.A.C.P

The Role Of Early Stress Testing In Assessing Low Risk Chest Pain Patients Admitted Through The Emergency Department

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

The 50-year Quest to Replace Warfarin: Novel Anticoagulants Define a New Era. CCRN State of the Heart 2012 June 2, 2012

Management of Pacing Wires After Cardiac Surgery

Type II Pulmonary Hypertension: Pulmonary Hypertension due to Left Heart Disease

Novartis Gilenya FDO Program Clinical Protocol and Highlights from Prescribing Information (PI)

SEX INCLUSION in CLINICAL TRIALS

ECG may be indicated for patients with cardiovascular risk factors

Antonio Colombo MD on behalf of the SECURITY Investigators

Data Management. Shanna M. Morgan, MD Department of Laboratory Medicine and Pathology University of Minnesota

Transcription:

30 Day Mortality Post Cardiac Event (Risk Scoring Systems) CENKER EKEN, MD ASSOCıATE PROFESSOR OF EMERGENCY MEDıCıNE AKDENıZ UNıVERSITY MEDICAL FACULTY

Disclosure; No conflict of interest.

ACI-TIPI Goldman Chest Pain Protocol

AHA Guideline, 2010

AHA 2015 Probability Classification TIMI Risk Score ADP = Risk scoring system + 0-2 hr ctn + normal EKG TIMI Vancouver

Probability&Risk Probability&Risk (TIMI) Probability&TIMI Risk - ADP

Probability & Isolated Risk scoring systems Accelerated Diagnostic Protocols Out In

What is challenging for ED phycians?

Challenge for ED Physicians? Prognosis of a definite acute coronary syndrome Prognosis of a patient with a probable acute syndrome.

55 years old Male Chest pain

Risk Scoring Systems for Patients with Acute Syndrome TIMI GRACE PURSUIT GUSTO

Risk Scoring Systems for Patients with Probaple Acute Coronary Syndrome TIMI GRACE North American Chest Pain Rule EDACS HEART Score Vancouver Chest Pain Rule

TIMI Risk Score Age 65 3 CAD Risk Factors Known CAD (Stenosis 50%) ASA Use in Past 7 days Severe angina ( 2 episodes in 24 hrs) EKG ST changes 0.5mm Positive Cardiac Marker

Antman EM, et al. The TIMI Risk Score for Unstable Angina/Non ST Elevation MIA Method for Prognostication and Therapeutic Decision Making. JAMA. 2000;284(7):835-842. doi:10.1001/jama.284.7.835

Study Sample Size Sensitivity ASPECT Study. 3582 %96.7 ADAPT Study. 1976 %97 Six AJ, et al. Crit Pathways in Cardiol 2013 Weisenthal et al. J Am Coll Cardiol. 2010. Macdonal SP, et al. Em Med Aust.2011 2906 %91.8 2819 %80 1666 %95.7 Chase et al. Ann Emerg Med. 2006 1458 %82 Cullen et al. Circulation 2013 948 %96.7

Study Sample Size Sensitivity Aldous et al. Acad Emerg Med. 2012. 940 %93.4 Cullen L, et al. Heart, Lung and Circulation Carlton EW, et al. Ann Emerg Med. 2015 Cullen et al. APACE study. J Am Coll Cardiol. 2013. Marcoon S, et al. Crit Pathways in Cardiol 2013 948 %96.6 963 %94.9 909 %99.4 8815 %2.4 Frequency (Adverse event) Backus et al. Int J Cardiol. 2013. 2388 %2.8 Frequency (TIMI 0-1) (Adverse event) Sun et al. Crit Pathways in Cardiol 2016 (Retrospective analysis of a prospective data) 8255 89.6%

Accelerated Diagnostic Protocol (TIMI=0 + normal EKG + 0-2 hr normal Tn) Study Sample Size Sensitivity Cardiac Enzyme ASPECT Trial 3582 99.3% ctn ADAPT Trial 1976 99.7% ctn Aldous et al. Int J Cardiol. 2014. 976 100% hsctni Macdonald SP et al. EMJ. 2013 1501 99% ctni Aldous et al. Acad Emerg Med. 2012. Cullen et al. APACE study. J Am Coll Cardiol. 2013. 940 99.6% ctni ve hstni 909 100% Mahlen et al. Acad Emerg Med 2015 (A secondary analysis) 1140 83.9% HsTnI and hstnt

Conclusion TIMI risk score should not be used a single tool to rule out the acute coronary syndrome in patients presenting with chest pain/suggestive symptoms. The sensitivity of ADP (TIMI (=0) + normal EKG + 0-2 hr ctn) is between %99-100 except a study by Mahlen et al.

100% What does a sensitivity represent? 100 MI patients No false negative 98% 90% 100 MI patients 100 MI patients 2 false negative 10 false negative

Eagle KA, et al. A Validated Prediction Model for All Forms of Acute. Coronary SyndromeEstimating the Risk of 6-Month Postdischarge Death in an International Registry. JAMA. 2004;291(22):2727-2733. doi:10.1001/jama.291.22.2727. GRACE Score

Study Sample Size Sensitivity Frequency MACE Score Cullen et al. Circulation. 2013 948 %98.9 0-50 Carlton EW, et al. Ann Emerg Med. 2015 963 %100 0-50 Backus et al. Int J Cardiol. 2013. 2388 -- %2.9 0-60

Conclusion GRACE score should not be used as a single tool to discharge patients from ED presenting with a probable ACS.

HEART Score

Studies Sample Size Sensitivity Frequence of MACE Six AJ, et al. Neth Heart J. 120 96.5% 0-3 points Marcoon S, et al. Crit Pathways in Cardiol 2013 8815 -- 3.6% Six AJ, et al. Crit Pathways in Cardiol 2013 2906 96.3% Backus et al. Int J Cardiol. 2013. 2388 -- 1.7% 0-3 points Carlton EW, et al. Ann Emerg Med. 2015 963 93.7% 0-3 points Mahler SA, et al. Int J Cardiol. 2013. 991 99.1% Score of 0-3 points and 0-3 hr Tn. Willems MNI, et al. Neth Heart J. 2014 89 100% hstnt

Studies Sample Size Sensitivity Frequence of MACE Bodopati et al. Emerg Med Aust 2016 (Retrospective analysis) Melki et al. Crit Pathways in Cardiol 2013 (Retrospective analysis) Backus et al. Crit Pathways in Cardiol 2010 (Retrospective analysis) Leite et al. BMC Cardiovascular Disorders 2015. (Retrospective analysis) Sun et al. Crit Pathways in Cardiol 2016 (Retrospective analysis of a prospective data) Mahler et al. Crit Pathw Cardiol. 2011 678 99% ctn 410 96.6% 7.3% ctn 880 98.1% 17.95% ctnt and ctni 223 90.0% 8255 85.8% 1070 58.3% Ultrasensitive TnI

Patient: Patients whom obtained EKG and Tn because the physician suspected the patient to have ACS. Intervention: HEART score of 0-3 & Baseline and 3 hr Tn levels are within normal limits; discharge the patient. Comparison: Usual care Outcome: Thirty day mortality, MI and revascularisation

141 vs 141 patients No difference for MACE Early discharge: %39.7 vs %18.4 Median length of ED stay 9.9 vs 21.9 hours

Chest pain at least five minutes in duration HEART score vs clinical gestalt Outcome: MI or adverse cardiac event 255 patients Outcome: %93 vs %87

Conclusion HEART score should not be used as a single tool for early discharge of patients. However, combining HEART score with 0-3 hr normal ctn levels may shorten the length of ED stay.

Vancouver Chest Pain Rules Christenson J, et al. A clinical prediction rule painfor early discharge of patients with chest pain. Ann Emerg Med. 2006;47:1-10.

Vancouver Chest Pain Rules Scheuermeyer FX, et al. Development and validation of a prediction rule for early discharge of low risk emergency department patients with potential ischemic chest pain. CJEM 2014;16(2):106-119

Studies Sample Size Sensitivity Algorithm Outcome Christenson J et al. Ann Emerg Med. 2006. 769 98.8% Previous Algorithm (Main Article) MI and USAP Jalili M, et al. Acad Emerg Med. 2012 593 95.1% Previous Algorithm MI and USAP Cullen et al. Am J Emerg Med. 2013. 1635 93.4% Previous Algorithm MI Scheuermeyer FX et al. CJEM 2014 763 100% New Algorithm Main Article Derivation Set MI and USAP Scheuermeyer FX et al. CJEM 2014 906 99.2% New Algorithm Main Article Validation Set MI and USAP Cullen et al. Am J Emerg Med. 2014. 1635 99.1 hstni% 98.8 cntni% New Algorithm MI and USAP Carlton EW, et al. Ann Emerg Med. 2015 963 100% New Algorithm hstni AMI

Conclusion The previous algorithm does not have a sufficient sensitivity. The current one Sensitivity is between 98.8% and 100% with ctn. Sensitivity is 100% with hstni (only one study)

EDACS

Data from the ADAPT trial was used. Patient: Chest pain at least five minutes in duration and planned to have further analysis for a possible ACS Outcome: 30 days adverse cardiac events.

Annals of Emergency Medicine 2016

Patient: Eligible patients were aged 18 years or older and presenting acutely from the community to the ED with possible cardiac symptoms suggestive of acute myocardial infarction for which the attending clinician(s) intended to perform serial troponin analysis to investigate for possible acute myocardial infarction. Intervention: ADAPT = TIMI-0 and 0-2 hr normal cardiac enzymes and normal EKG. Comparison: EDACS-ADP: EDACS < 16, 0-2 hr normal cardiac enzymes and normal EKG. Outcome: The primary outcome was successful discharge, defined as discharge from the hospital within 6 hours of ED arrival and without major adverse cardiac event within 30 days.

A secondary analysis of HEART Pathway study outlined before.

The EDACS-ADP identified 188/282 patients (66.7%, 95% CI: 60.8% 72.1%) as low risk. EDACS-ADP was 88.2% (95% CI: 63.6% 98.5%) sensitive for MACE, identifying 15/17 patients with MACE

Conclusion EDACS-ADP is a promising scoring system due to the findings of the main study. However, further prospective data is still needed to validate the EDACS-ADP.

North American Chest Pain Rule

North American Chest Pain Rule Patient: Anterior chest pain patients whom obtained ctn by the physician. STEMI patients excluded. Standard ctn levels were measured. Outcome: 30 days adverse cardiac event.

A secondary analysis of prospectively collected data (MIDAS study)

Clinical Gestalt (Likert Scale 1, 0-3 hr Tn North American Chest Pain Rule (0-3 hr Tn) HEART Score (score of 0-3 and 0-3 hr Tn)

Conclusion North American Chest Pain Rule is a sensitive tool for ruling out adverse cardiac events in patient presenting with symptoms associated with an acute coronary syndrome.

Pitfalls in Studies Trialing the Risk Scores Differences among the outcomes (diversies in adverse cardiac events) Variations in Troponin measurements (ctn vs hstn, TnI vs TnT) Variations in selection of study samples Patients included to the studies ignoring the onset of sypmtoms. At this case, chest pain with a so early onset (within one hour) should be observed more.

Any Questions or Comments?